SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 14, 2003
AVI BioPharma, Inc.
(Exact name of registrant as specified in its charter)
|
Oregon |
|
0-22613 |
|
93-0797222 |
|
(State or other jurisdiction of incorporation or organization) |
|
(Commission File Number) |
|
(IRS Employer Identification Number) |
One S.W. Columbia, Suite 1105
Portland, OR 97258
(Address of principal executive offices)
(503) 227-0554
Registrant’s telephone number, including area code
Item 5. Other Events and Regulation FD Disclosure.
The information set forth below pursuant to Item 12 shall also be deemed filed pursuant to Item 5.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
|
Exhibit Number |
|
Description |
|
99.1 |
|
Press Release dated November 14, 2003 announcing the withdrawal of the offering under the prospectus supplement filed with the SEC on October 30, 2003. |
Item 12. Results of Operations and Financial Condition.
AVI BioPharma, Inc. (the “Company”) issued a press release on November 14, 2003, before the opening of trading in its Common Stock on the Nasdaq National Market System. A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated herein by reference.
The Press Release announces the withdrawal of the offering under the prospectus supplement filed with the SEC on October 30, 2003.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Portland, State of Oregon, on November 14, 2003.
|
AVI BioPharma, Inc. |
||
|
|
|
|
|
By: |
/s/ ALAN P. TIMMINS |
|
|
|
Alan P. Timmins |
|
|
|
President and Chief Operating Officer |
|
|
|
(Principal Operating Officer) |
|
2